Payment overview · 2025
General Payments
$1,876.80
86 reported records · 25 companies
Healthcare provider profile · identity verified
Thomas E Gribbin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND RAPIDS, MI · NPI 1639179286
Verified facts
What the public records show
CMS Open Payments records show Thomas E Gribbin, M.D. received $1,876.80 in general payments during 2025 across 86 reported records.
Novartis Pharmaceuticals Corporation accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibrance.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ibrance by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Calquence by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CERDELGA as an associated drug or biological on 587 records involving 387 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Cerdelga by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jakafi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $298.22 | 15.9% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.26 | 12.5% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $233.62 | 12.4% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $200.84 | 10.7% | 12 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $111.48 | 5.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.76 | 5.6% | 11 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $77.77 | 4.1% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $75.91 | 4.0% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $74.88 | 4.0% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $54.28 | 2.9% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $51.77 | 2.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $50.16 | 2.7% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $37.66 | 2.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $35.54 | 1.9% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $28.34 | 1.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.23 | 1.4% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $24.57 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.94 | 1.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.08 | 1.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.66 | 1.2% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 1.1% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $17.54 | 0.9% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $17.49 | 0.9% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $16.08 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.72 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,745.06 | 83 |
| Education | $131.74 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $240.62 | 13 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $199.74 | 7 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $162.84 | 9 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $159.84 | 5 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $125.01 | 4 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $111.48 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $93.16 | 8 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $77.77 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $75.91 | 4 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $73.45 | 7 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $68.49 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $57.60 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $54.28 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $51.77 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $50.45 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $38.00 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $37.66 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $31.31 | 4 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $31.31 | 4 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ONGLYZA Normalized: onglyza |
Drug | AstraZeneca Pharmaceuticals LP | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | CERDELGA open payments reported associated product |
CMS Open Payments — General Payments 587 supporting records · 387 recipient NPIs · example record 1233194948 |
Cerdelga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 336 | 112 |
| Tamoxifen Citrate | Tamoxifen Citrate | 295 | 92 |
| Acyclovir | Acyclovir | 188 | 30 |
| Calquence | Acalabrutinib Maleate | 85 | suppressed |
| Exemestane | Exemestane | 61 | 20 |
| Letrozole | Letrozole | 60 | 18 |
| Hydroxyurea | Hydroxyurea | 49 | 13 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 49 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | suppressed |
| Nyvepria | Pegfilgrastim-Apgf | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Eliquis | Apixaban | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Ibrance | Palbociclib | 22 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 20 | suppressed |
| Neulasta | Pegfilgrastim | 17 | suppressed |
| Omeprazole | Omeprazole | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pomalyst | Pomalidomide | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | 13 |
| Olanzapine | Olanzapine | 14 | 13 |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 13 | suppressed |
| Cerdelga | Eliglustat Tartrate | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,876.80 · 86 records | Novartis Pharmaceuticals Corporation | ADCETRIS, ALYMSYS, BLENREP, BRAFTOVI, BRUKINSA, DATROWAY, ELREXFIO, ENHERTU, FOTIVDA, Fabhalta, IBRANCE, IMFINZI, Itovebi, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LORBRENA, LYNPARZA, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, OJJAARA, ONGLYZA, OPDUALAG, Onivyde, POTELIGEO, PYRUKYND, RYTELO, SARCLISA, TEVIMBRA, TUKYSA, Trodelvy, VENCLEXTA, Vonjo, ZYNYZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibrance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARRAY BIOPHARMA INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error